CARLSBAD, Calif., March 03, 2022 — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants announced today that it has completed the world’s first DEXA-C implantation at Cypress Pointe Surgical Hospital in Louisiana, where the implant density was directly matched with the patient’s bone quality.
Trent Northcutt, CEO and President at Aurora Spine said, “It’s a significant milestone for Aurora to announce the completion of the world’s first surgical implantations of the DEXA-C patient-bone-density matched interbody devices. The DEXA-C implants, a line of cervical cages for anterior cervical discectomy with fusion (ACDF) procedures, are the first of its kind in the world by offering an implant based upon a patient’s bone density. It is also the first color-coded implant on the marketplace and will help doctors match against the color-coding of a DEXA score.”
Dr. Sebastian Koga, Neurosurgeon at Koga Neurosurgery in Covington, Louisiana said, “The DEXA-C implant from Aurora Spine ushers in a new era of personalized spine surgery. This customization prevents implant subsidence and accelerates fusion even in healthy individuals. This will expand access to spine surgery for older patients who were previously excluded by poor bone quality.”
A recently published, peer-reviewed research article at https://pubmed.ncbi.nlm.nih.gov/34934366 demonstrated the need for novel spinal implants. Reviewing the history of spinal implants the authors concluded that patients’ bone quality has not been previously used to guide manufacturing. Aurora’s DEXA-C implants are the first in the world to match a patient’s bone density and quality to a personalized implant. Quoting the article, “With an increasingly aging population globally, a confluence has emerged between the rising prevalence of degenerative spinal disease and osteoporosis. Fusion of the anterior spinal column remains the mainstay surgical intervention for many spinal degenerative disorders. However, decreased vertebral bone mineral density (BMD), quantitatively measured by traditional DEXA scanners or portable, R.E.M.S. Technology (Radiofrequency Echographic Multi Spectrometry) based bone densitometry scanner, complicates treatment with surgical interbody fusion as weak underlying bone stock increases the risk of post-operative implant-related adverse events, including cage subsidence. There is a necessity for developing cages with advanced structural designs that incorporate bioengineering and architectural principles to tailor the interbody fusion device directly to the patient’s BMD status. Specifically, lattice-designed cages that mimic the web-like structure of native cancellous bone have demonstrated excellent resistance to post-operative subsidence. Aurora’s DEXA-C spinal interbody implant designed intentionally to simulate the lattice structure of human cancellous bone, with a similar modulus of elasticity, and specialized to match a patient’s bone status across the BMD continuum. The implant incorporates an open pore design where the degree of pore compactness directly corresponds to the patient’s DXA-defined BMD status, including patients with osteoporosis.”
Dr. Koga continued, “These initial surgeries confirmed my belief about the support provided by the Echolight bone scanner before the operation, and the software generated instant report. Based on the report we can select the appropriate density implant from the DEXA-C range. For the first time we can use a hand-held ultrasound probe to scan a patient’s bone density and choose the best spinal implant matching to their bone quality. Aurora Spine has developed the DEXA family of implants which mimic the natural bone of patients with osteopenia and osteoporosis. Aurora’s DEXA Platform, supported by Echolight, is likely to have significant advantages by providing cervical fusion candidates with a one-stop shop for patient matched implants based on quick and accurate real-time bone quality analysis with immediately available accurate T-score reports minutes before surgery.”
Laszlo Garamszegi, Chief Technology Officer of Aurora Spine stated, “Aurora’s DEXA Technology includes X-ray readable Density Markers that can visually confirm if low, medium or high-density devices were implanted in a particular patient. We think that for the first time, patients worldwide will benefit when they are able to receive fusion implants that match their own bone.”
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
asapf@lythampartners.com
